港股異動丨歌禮制藥大跌超10%,先舊後新折價配股,大股東減持套現3.9億
昨日創出歷史新高的歌禮制藥(1672.HK)今日盤初大跌超10%,報16.4港元,截至目前成交9.1億港元。消息面上,歌禮制藥以先舊後新方式配股,配股價每股16.45港元,所得款項總額及淨額分別爲4.74億港元及4.68億港元。淨額中,約90%建議用於其皮下注射多肽及口服多肽候選藥物有關的肥胖症臨牀試驗研發,約10%建議用作營運資金及其他一般公司用途。控股股東、公司創辦人吳勁梓按每股16.45港元的價格出售5240萬股股份,及認購2882萬股新股,套現約3.88億港元。緊隨配售及認購完成後,控股股東持股將由62.21%降至58.03%。配股價16.45港元較昨日收市價18.26港元折讓9.91%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.